Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.

Literature DB >> 9527812

In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.

Abstract

In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 microg/ml.

Entities: Chemical Species

Mesh：

Substances：

Year: 1998 PMID： 9527812 PMCID： PMC105440 DOI： 10.1128/AAC.42.2.471

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

7 in total

1. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

Authors: P Belanger; C C Nast; R Fratti; H Sanati; M Ghannoum
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

2. The hidden danger of primary fluconazole prophylaxis for patients with AIDS.

Authors: J Berg; C J Clancy; M H Nguyen
Journal: Clin Infect Dis Date: 1998-01 Impact factor: 9.079

Review 3. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors: J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal: Clin Infect Dis Date: 1997-02 Impact factor: 9.079

4. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.

Authors: M Ruhnke; A Schmidt-Westhausen; M Trautmann
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

5. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors: M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

6. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.

Authors: M V Martin; J Yates; C A Hitchcock
Journal: Antimicrob Agents Chemother Date: 1997-01 Impact factor: 5.191

7. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors: A L Barry; S D Brown
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

7 in total

24 in total

1. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Authors: T Yamazumi; M A Pfaller; S A Messer; A Houston; R J Hollis; R N Jones
Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191

2. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors: M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

3. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors: S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191

4. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.

Authors: M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; J H Rex
Journal: J Clin Microbiol Date: 1999-09 Impact factor: 5.948

5. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Authors: P Mondon; R Petter; G Amalfitano; R Luzzati; E Concia; I Polacheck; K J Kwon-Chung
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

6. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors: L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

7. The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.

Authors: R Mdodo; K Brown; E Omonge; W Jaoko; J Baddley; P Pappas; M Colette Kempf; I Aban; S Odera; A Suleh; P E Jolly
Journal: East Afr Med J Date: 2010-12

8. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors: C J Clancy; M H Nguyen
Journal: Eur J Clin Microbiol Infect Dis Date: 1998-08 Impact factor: 3.267

Review 9. Current and emerging azole antifungal agents.

Authors: D J Sheehan; C A Hitchcock; C M Sibley
Journal: Clin Microbiol Rev Date: 1999-01 Impact factor: 26.132

10. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors: Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal: Antimicrob Agents Chemother Date: 2008-01-22 Impact factor: 5.191